SUMMER 2020
RiverVest celebrates 20 years of science, strategy and innovation
Portfolio News
RiverVest re-upped in Amplyx Pharmaceutical’s $90M Series C financing.
RiverVest re-upped in Avalyn Pharma's $35.5M Series B financing, just as the biopharma innovator advanced three therapeutic programs for pulmonary fibrosis and chronic lung allograft dysfunction through clinical trials.
Dublin-based Horizon Therapeutics acquired Curzion Pharmaceuticals, co-founded by RiverVest Venture Partners in 2019, for $45M upfront with additional payments based on milestones. This resulted in a 6x multiple for RiverVest.
Mirum Pharmaceuticals, co-founded by RiverVest in 2018, advances its investigational treatment for Alagille Syndrome closer to FDA approval.

Reneo, co-founded by RiverVest in 2018, readies for global test of drug for rare mitochondrial disease.
Xilio hired a talented Chief Medical Officer with a long and distinguished career in immuno-oncology drug development.
Case Studies
Allakos: reining in the immune system
InterVene: Medical device game-changer in the making
Lumena: transformative medicines for liver diseases
RiverVest News
ANNUAL MEETING

RiverVest held its annual meeting with limited partners in April (virtually), announcing:

  • the firm’s new brand and new website, better reflecting the work it does “improving the lives of patients, supporting entrepreneurs, and earning the trust of investors through science, strategy and innovation;” and

  • RiverVest portfolio companies have been involved in the development of 26 commercial products now treating patients.

RESULTS
People
Arch Oncology appointed biotech veteran Julie Hambleton, MD to Arch's board of directors.
InterVene named Jeff Elkins new CEO as former CEO Fletcher Wilson moved to Charlottesville, VA, and shifted his role to founder.
Jeff Elkins, CEO InterVene
Washington University graduate Andrew Kleiboeker joined RiverVest as analyst.
Managing Director Nancy Hong served as a panelist at the first Xconomy digital webcast and discussed the San Diego biotech ecosystem at the Xcelerating Life Sciences San Diego event.
RiverVest’s newest Managing Director Derek Rapp and his family were featured in a recent article by the JDRF (Juvenile Diabetes Research Foundation).
STAY CONNECTED
RiverVest is a leading venture capital firm building life sciences companies to
address significant unmet needs of patients and deliver top-quartile returns to
investors.